Finance ❯ Corporate Finance ❯ Earnings Reports ❯ Revenue Growth

Xeris Biopharma Financial Performance

Xeris Biopharma Sets 2026 Revenue Outlook at $375–$390 Million, Targets H2 Start for XP-8121 Phase III

2025 profitability positions the company to step up 2026 investment focused on growth plus exclusivity protection.